The company's novel approach uses stem cells harvested from the patient's own bone marrow into which a healthy version of the disease causing gene is inserted. At the heart of bluebird bio's product creation efforts is its broadly applicable gene therapy platform for the development of novel treatments for diseases with few or no clinical options. Research shows that this approach results in long lasting clinical remission in cancer patients and protective immunity against infections.īluebird bio USA Listed bluebird bio is developing innovative gene therapies for severe genetic disorders. They employ messenger RNA to unleash and boost a patient’s immune response against a tumor or infectious agent. Our pipeline includes development candidates for mRNA-based vaccines and therapies spanning several therapeutic areas, and we have multiple clinical trials underway with other development candidates progressing toward the clinic.ĮTheRNA Immunotherapies Belgium Private eTheRNA immunotherapies is developing first in class mRNA immunotherapies for the treatment of cancer and infectious diseases. Since our founding in 2010, we have worked to build the industry's leading mRNA technology platform, the infrastructure to accelerate drug discovery and early development, a rapidly expanding pipeline, and a world-class team. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured. Moderna Therapeutics USA Private We are pioneering a new class of medicines made of messenger RNA, or mRNA. Stemirna’s current pipeline include personalized cancer vaccines and prophylactic vaccines for infectious diseases. Taking advantage of its two innovative mRNA platforms – a comprehensive mRNA delivery platform and an IVT-mRNA synthesis platform – Stemirna Therapeutics turns the patient’s body into a drug factory that produces medicines for itself. Stemirna Therapeutics China Private As the first biotech company in China to focus on mRNA therapeutics, Stemirna strives to deliver novel cure for patients in the world. In addition, Heat is also developing a pipeline of proprietary immunomodulatory antibodies, including PTX-35 which is enrolling in a Phase 1 trial. The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in its Phase 2 trial, HS-130 in Phase 1, and a COVID-19 vaccine program in preclinical development. The company's gp96 platform is designed to activate immune responses against cancer or pathogenic antigens. Heat Biologics USA Listed Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. CureVac Germany Private CureVac is a leading clinical stage biotechnology company in the field of messenger RNA (mRNA) technology with 20 years of expertise in developing and optimizing this versatile molecule for medical purposes.
0 kommentar(er)
